Development of novel pancreatic cancer peptide vaccine therapy using invasion regulating gene

2017 Fiscal Year Final Research Report

• Project/Area Number: 16K19950
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Digestive surgery
• Research Institution: Wakayama Medical University
• Principal Investigator: SHIMIZU Atsushi 和歌山県立医科大学, 医学部, 博士研究員 (00637910)
• Project Period (FY): 2016-04-01 – 2018-03-31
• Keywords: MUC16 / Mesothelin / peptide vaccine therapy / pancreas cancer

Outline of Final Research Achievements

MUC16 and Mesothelin are invasion regulatory genes for pancreatic cancer and research on the identification of epitope peptides for these genes was conducted. By using the BIMAS database, 22 kinds and 19 kinds of amino acid sequences as candidates for epitopes having affinity for MUC16 and Mesothelin-derived HLA-A2402 were assumed respectively, and using peripheral blood mononuclear cells (PBMC) derived from healthy volunteers It was investigated whether each cytotoxic T lymphocyte (CTL) could be induced or not. It was suggested that specific CTLs were induced in 2 (MUC16) and 5 (Mesothelin) kinds of peptides. If it is proved that these CTL clones have cytotoxic activity against pancreatic cancer cell line, it is considered that effective pancreatic cancer peptide vaccine therapy can be developed.

Free Research Field

膵癌治療